IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation.

Jie Sun,Xiaobao Zhang,Susu Zhang,Xiang Zhang,Yanning Qian,Hongquan Dong

doi:10.1186/s12974-015-0394-5

Abstract

BackgroundNeuroinflammation is considered a risk factor for impairments in neuronal function and cognition that arise with trauma, infection, and/or disease. IL-17A has been determined to be involved in neurodegenerative diseases such as multiple sclerosis. Recently, IL-17A has been shown to be upregulated in lipopolysaccharide(LPS)-induced systemic inflammation. This study aims to explore the role of IL-17A in LPS-induced neuroinflammation and cognitive impairment.MethodsMale Sprague–Dawley (SD) rats were injected intraperitoneally with LPS (500 μg/kg), and IL-17A expression in serum and in the hippocampus was examined 6, 12, 24, and 48 h later. Then, we investigated whether IL-17A-neutralizing antibodies (IL-17A Abs, 1 mg/kg) prevented neuroinflammation and memory dysfunction in aged rats that received LPS (500 μg/kg) injection. In addition, the effect of IL-17A on microglial activation in vitro was determined using ELISA and immunofluorescence.ResultsLPS injection increased the expression of IL-17A in serum and in the hippocampus. IL-17A Abs improved LPS-induced memory impairment. In addition, IL-17A Abs prevented the LPS-induced expression of TNF-α, IL-6 and inflammatory proteins, and of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) as well as the activation of microglia in the brain. IL-17A Abs also inhibited the expression of amyloid precursor protein (APP) and BACE1 and increased the expression of the synaptic marker PSD95 in the aged rats treated with LPS. In an in vitro study, we found that recombinant IL-17A could simulate microglial activation and increase production of pro-inflammatory cytokines.ConclusionTaken together, our results suggest that IL-17A was involved in LPS-induced neuroinflammation and cognitive impairment in aged rats via microglial activation. Anti-IL-17A may represent a new therapeutic strategy for the treatment of endotoxemia-induced neuroinflammation and cognitive dysfunction.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-015-0394-5) contains supplementary material, which is available to authorized users.

Highlights

Neuroinflammation plays a key role in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis (MS) and in memory impairment [1,2,3]
Increases of IL-17A expression induced by LPS To examine whether IL-17A is involved in LPS-induced neuroinflammation, we studied IL-17A protein expression levels in the serum and in the hippocampus within 48 h after LPS injection
140.41 ± 10.59 pg/ml, 12-h group 161.66 ± 16.33 pg/ml, 24-h group 120.50 ± 11.55 pg/ml, P < 0.01, Fig. 2b). These results indicate that IL-17A may be involved in LPS-induced neuroinflammation

Summary

Introduction

Neuroinflammation plays a key role in neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis (MS) and in memory impairment [1,2,3]. It has been reported that microglia likely play an important role in either the development of protective immune responses or in the progression of damaging inflammation during central nervous system (CNS) disease states [8]. IL-17A is strongly involved in mediating pro-inflammatory responses via the induction of many other cytokines, including IL-6, TGF-β, and TNF-α as well as the induction of chemokines, including IL-8 and monocyte chemotactic protein-1 (MCP-1), in many cell types [12]. The present study aims to explore the role of IL-17A in LPS-induced neuroinflammation and cognitive impairment. This study aims to explore the role of IL-17A in LPS-induced neuroinflammation and cognitive impairment

Objectives

Methods

Results

Discussion

Conclusion